Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.

By E. Flossmann, Peter M. Rothwell. The Lancet, 2007

804 citations recorded by the source corpus.

Subfields: Immunology, Pharmacology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/c620b0274d65a168466325e174b0aaccf302f4c9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. A. Mantovani
2. A. Sica
3. P. Allavena
4. F. Balkwill
5. D. Hanahan
6. Lisa M. Coussens
7. J. Pollard
8. M. Karin

In Pharmacology

1. F. Balkwill

In Psychiatry and Mental health

1. P. Allavena
2. A. Sica
3. A. Mantovani
4. F. Balkwill
5. M. Karin
6. Lisa M. Coussens
7. J. Pollard

Citations in the corpus

• Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival (2012, neutral): “Poorly differentiated 78/958 (8) 39/461 (8) 26/337 (8) 9/94 (10) 4/66 (6)”
• Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: A window of opportunity for ovarian cancer chemoprevention (2017, background): “For colorectal cancer prevention, theUSPreventive Service Task Force is recommending 81 mg of aspirin daily (48), based on two large randomized clinical trials (49, 50).”
• Cancer-related inflammation (2008, background): “Accordingly, treatment with non-steroidal anti-inflammatory agents decreases the incidence of, and the mortality that results from, several tumour type”